Home » Stocks » OTIC

Otonomy, Inc. (OTIC)

Stock Price: $2.43 USD 0.07 (2.97%)
Updated Jun 16, 2021 4:00 PM EDT - Market closed
Market Cap 137.58M
Revenue (ttm) 203,000
Net Income (ttm) -45.18M
Shares Out 52.32M
EPS (ttm) -0.98
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 16
Last Price $2.43
Previous Close $2.36
Change ($) 0.07
Change (%) 2.97%
Day's Open 2.38
Day's Range 2.36 - 2.46
Day's Volume 204,102
52-Week Range 2.01 - 6.98

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

SAN DIEGO, June 15, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the initia...

1 day ago - GlobeNewsWire

Otonomy Inc (NASDAQ: OTIC) may have hit a snag with the development of its lead ear disorder candidate Otividex. Still, the company is trumpeting an early win for a gene therapy designed to treat congen...

1 month ago - Benzinga

OTO-825 administration rescues hearing and cochlear damage in two preclinical models of congenital hearing loss caused by GJB2 deficiency OTO-825 administration rescues hearing and cochlear damage in tw...

1 month ago - GlobeNewsWire

Conference call and webcast today at 4:30 p.m. ET

1 month ago - GlobeNewsWire

SAN DIEGO, May 04, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will rep...

1 month ago - GlobeNewsWire

AAV-mediated gene therapy rescues hearing and cochlear damage in two preclinical models of congenital hearing loss caused by GJB2 deficiency AAV-mediated gene therapy rescues hearing and cochlear damage...

1 month ago - GlobeNewsWire

SAN DIEGO, April 19, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the closi...

1 month ago - GlobeNewsWire

SAN DIEGO, April 07, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the prici...

2 months ago - GlobeNewsWire

SAN DIEGO, April 07, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that it h...

2 months ago - GlobeNewsWire

SAN DIEGO, April 06, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced its parti...

2 months ago - GlobeNewsWire

SAN DIEGO, April 05, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the prese...

2 months ago - GlobeNewsWire

Investors need to pay close attention to Otonomy (OTIC) stock based on the movements in the options market lately.

3 months ago - Zacks Investment Research

SAN DIEGO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that manag...

3 months ago - GlobeNewsWire

Otonomy Inc (NASDAQ: OTIC) has reported topline data from Phase 3 trial evaluating OTIVIDEX in patients with Ménière's disease. It is an inner ear disorder that causes episodes of vertigo (spinning) and...

3 months ago - Benzinga

SAN DIEGO, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that the P...

3 months ago - GlobeNewsWire

SAN DIEGO, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced multiple p...

3 months ago - GlobeNewsWire

Conference call and webcast today at 4:30 p.m. ET

4 months ago - GlobeNewsWire

SAN DIEGO, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will re...

4 months ago - GlobeNewsWire

OTIC failed a phase 3 trial and fell from $20 to $5, and hasn't recovered since despite succeeding in another phase 3. A tiebreaker third phase 3 is ongoing with data by 1Q2021.

5 months ago - Seeking Alpha

SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that manag...

5 months ago - GlobeNewsWire

SAN DIEGO, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced positive t...

5 months ago - GlobeNewsWire

Otonomy (OTIC) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

6 months ago - Zacks Investment Research

SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today provided updates reg...

6 months ago - GlobeNewsWire

SAN DIEGO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that manag...

7 months ago - GlobeNewsWire

Otonomy, Inc. (OTIC) CEO David Weber on Q3 2020 Results - Earnings Call Transcript

7 months ago - Seeking Alpha

Otonomy (OTIC) delivered earnings and revenue surprises of 12.00% and -54.55%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

7 months ago - Zacks Investment Research

Otonomy, Inc. (OTIC) CEO David Weber On Q3 2020 Results - Quick Version Earnings Call Transcript

7 months ago - Seeking Alpha

Shares of Otonomy (NASDAQ:OTIC) were flat after the company reported Q3 results. Quarterly Results Earnings per share were up 33.33% over the past year to ($0.22), which beat the estimate of ($0.24).

7 months ago - Benzinga

Conference call and webcast today at 4:30 p.m. ET

7 months ago - GlobeNewsWire

SAN DIEGO, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will re...

7 months ago - GlobeNewsWire

SAN DIEGO, Oct. 02, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the comple...

8 months ago - GlobeNewsWire

Investors need to pay close attention to Otonomy (OTIC) stock based on the movements in the options market lately.

9 months ago - Zacks Investment Research

SAN DIEGO, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that ma...

9 months ago - GlobeNewsWire

Otonomy, Inc. (OTIC) CEO David Weber on Q2 2020 Results - Earnings Call Transcript

10 months ago - Seeking Alpha

Otonomy (OTIC) delivered earnings and revenue surprises of -2.78% and -92.06%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

10 months ago - Zacks Investment Research

Compound has potential to benefit patients with severe hearing loss Compound has potential to benefit patients with severe hearing loss

10 months ago - GlobeNewsWire

Webcast and Conference Call to be Held at 5 p.m. EDT on August 4, 2020 Webcast and Conference Call to be Held at 5 p.m. EDT on August 4, 2020

10 months ago - GlobeNewsWire

SAN DIEGO, July 13, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the clos...

11 months ago - GlobeNewsWire

Otonomy (OTIC) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

11 months ago - Zacks Investment Research

SAN DIEGO, July 09, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the pric...

11 months ago - GlobeNewsWire

SAN DIEGO, July 08, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that it ...

11 months ago - GlobeNewsWire

Otonomy (NASDAQ: OTIC) shares are trading higher on Tuesday. The company reported results from its Phase 1/2 clinical trial of OTO-313 in patients with Tinnitus demonstrated a higher proportion of respo...

11 months ago - Benzinga

SAN DIEGO, July 06, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced positive...

11 months ago - GlobeNewsWire

Management will review the OTIVIDEX statistical analysis plan update together with the positive top-line OTO-313 Phase 1/2 trial results during a conference call today at 4:30 p.m. ET Management will re...

11 months ago - GlobeNewsWire

Conference call and webcast today at 4:30 p.m. ET

1 year ago - GlobeNewsWire

Otonomy (OTIC) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

1 year ago - Zacks Investment Research

SAN DIEGO, June 11, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that Dav...

1 year ago - GlobeNewsWire

SAN DIEGO, June 10, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that due...

1 year ago - GlobeNewsWire

Conference call to review status of clinical trials and timing to results to be held in June Conference call to review status of clinical trials and timing to results to be held in June

1 year ago - GlobeNewsWire

SAN DIEGO, April 09, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today provided a busin...

1 year ago - GlobeNewsWire

About OTIC

Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. It also develops OTIVIDEX, a sustained-exposure formulation of the steroid dexamethasone that has completed Phase III clinical trial for the treatment of Ménière's disease; OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which has completed Phase I/II clinica... [Read more...]

Industry
Biotechnology
IPO Date
Aug 13, 2014
CEO
David Weber
Employees
56
Stock Exchange
NASDAQ
Ticker Symbol
OTIC
Full Company Profile

Financial Performance

In 2020, Otonomy's revenue was $273,000, a decrease of -54.50% compared to the previous year's $600,000. Losses were -$44.73 million, 0.13% more than in 2019.

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for Otonomy stock is "Strong Buy." The 12-month stock price forecast is 5.63, which is an increase of 131.69% from the latest price.

Price Target
$5.63
(131.69% upside)
Analyst Consensus: Strong Buy